semaglutide off patent Ozempic, Wegovy and Rybelsus: The patents behind Novo Nordisk's weight-loss drugs Indian pharma launches low-cost Ozempic

Description

Today, we announced our investigational glucagon/GLP-1 dual receptor agonist achieved key measures of success at 48 weeks in our IMPACT Phase 2b trial and recent interactions with the FDA have resulted in alignment on the parameters for a registrational Phase 3 trial

By David Prince, MD | Montefiore Medical Center Although new GLP-1 agonist weight loss drugs such as Ozempic, Wegovy, Trulicity, and Byetta are currently dominating the headlines, the majority of overweight Americans may not qualify for these medications due to limited availability and insurance plan restrictions

Can Cloudy Urine Be a Sign of Diabetes?

(Nasdaq: ALT), a late clinical-stage biopharmaceutical company developing pemvidutide to address serious liver diseases, today announced that it will report its first quarter 2026 financial results on Wednesday, May 13, 2026